Financial Modeling From Tufts Center for the Study of Drug Development Demonstrates Substantial Net Benefits to Sponsors Who Use Decentralized Clinical Trials (DCTs) Technology
The data is conclusive, DCTs provide better returns on investment than traditional trials. In fact, new analysis by Tufts CSDD shows DCTs can provide up to 13x ROI in phase III trials & 5x ROI in phase II trials through reductions in clinical trial cycle time, screen failure decreases, and more. Learn more with your free copy of the analysis.
New Strategies for a Better Glycosylation Profile
January 22nd 2025Glycan analysis provides key information on critical quality attributes that could affect stability, safety and efficacy of a protein therapeutic. Specific needs for understanding the glycosylation profiles change throughout the drug development process, but the requirement for high-resolution glycan information remains the same and is essential to help ensure product quality.
